1,220 institutions hold shares in Novartis AG (NVS), with 67.7k shares held by insiders accounting for 0.00% while institutional investors hold 10.08% of the company’s shares. The shares outstanding are 2.26B, and float is at 2.11B with Short Float at 0.25%. Institutions hold 10.08% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Primecap Management Company with over 21.81 million shares valued at $2.06 billion. The investor’s holdings represent 0.88% of the NVS Shares outstanding. As of Dec 30, 2020, the second largest holder is Dodge & Cox Inc with 21.62 million shares valued at $2.04 billion to account for 0.88% of the shares outstanding. The other top investors are Loomis Sayles & Company, LP which holds 20.12 million shares representing 0.82% and valued at over $1.9 billion, while Bank of America Corporation holds 0.40% of the shares totaling 9.81 million with a market value of $926.39 million.
Novartis AG (NYSE: NVS) is -8.40% lower on its value in year-to-date trading and has touched a low of $69.18 and a high of $98.52 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NVS stock was last observed hovering at around $87.91 in the last trading session, with the day’s loss setting it -1.41% off its average median price target of $105.00 for the next 12 months. It is also 33.25% off the consensus price target high of $129.58 offered by 26 analysts, but current levels are 3.63% higher than the price target low of $89.76 for the same period.
Currently trading at $86.50, the stock is -5.26% and -6.23% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.11 million and changing -1.60% at the moment leaves the stock -1.59% off its SMA200. NVS registered -3.97% loss for a year compared to 6-month gain of 0.12%. The firm has a 50-day simple moving average (SMA 50) of $92.75 and a 200-day simple moving average (SMA200) of $88.70.
The stock witnessed a -10.73% loss in the last 1 month and extending the period to 3 months gives it a -0.80%, and is -5.42% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 0.87% over the week and 1.24% over the month.
Novartis AG (NVS) has around 105794 employees, a market worth around $214.89B and $49.90B in sales. Current P/E ratio is 24.59 and Fwd P/E is 12.80. Profit margin for the company is 16.20%. Distance from 52-week low is 25.04% and -12.20% from its 52-week high. The company has generated returns on investments over the last 12 months (8.80%).
Novartis AG (NVS) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Novartis AG (NVS) is a “Overweight”. 26 analysts offering their recommendations for the stock have an average rating of 1.00, where 7 rate it as a Hold and 2 think it is a “Overweight”. 15 of the analysts rate the stock as a “Buy”. 2 analysts have rated the stock as a Sell or Underperform.
Novartis AG is expected to release its quarterly report on 04/27/2021 and quarterly earnings per share for the current quarter are estimated at $1.64 with sales reaching $13.11B over the same period.The EPS is expected to grow by 14.20% this year, but quarterly earnings will post 7.50% year-over-year. Quarterly sales are estimated to grow 6.70% in year-over-year returns.
Novartis AG (NVS) Insider Activity
The most recent transaction is an insider purchase by Novartis Bioventures Ltd, the company’s Former 10% Owner. SEC filings show that Novartis Bioventures Ltd bought 125,000 shares of the company’s common stock on Jun 30 at a price of $17.00 per share for a total of $2.13 million. Following the purchase, the insider now owns 1.18 million shares.
Novartis AG (NVS): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 9.96% up over the past 12 months. Bristol-Myers Squibb Company (BMY) is -5.08% down on the 1-year trading charts. Short interest in the company’s stock has risen 17.2% from the last report on Dec 30, 2020 to stand at a total of 4.43 million short shares sold with a short interest ratio of 2.41.